Clinical Trial

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

Study acronym: SEDATE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-02-20; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2024-06-03
Trial Details
NCT Number NCT06281977
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions Ventricular Tachycardia, Ventricular Arrhythmias, Ventricular Fibrillation, Recurrent Ventricular Tachycardia
Enrollment 192 participants
Start Date 2024-05-08
Primary Completion 2027-05-08 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-07